Purpose The adjunctive ablation of areas of complex fractionated electrogram (CFE) to pulmonary vein isolation (PVI) is an emerging strategy for patients with non-paroxysmal atrial fibrillation (AF). We studied the long-term outcomes of this approach. Methods Sixty-six patients (mean age 58±9, 86.4 % male) with non-paroxysmal AF underwent ablation procedures consisting of PVI plus extensive CFE ablation. Post-ablation atrial tachycardia (AT) was also targeted if presented. All patients were followed up regularly on an ambulatory basis by means of ECG and Holter recordings.
Introduction
Since the discovery of ectopic electrical activity within the pulmonary veins, both the technology and the techniques involved in catheter ablation for atrial fibrillation (AF) have been developed. Although it was initially introduced as a treatment for paroxysmal AF, catheter ablation is today increasingly offered to non-paroxysmal AF patients [1] [2] [3] [4] [5] [6] [7] . Until recently, pulmonary vein isolation (PVI) has been the cornerstone of paroxysmal AF ablation, but it has failed to produce similar results in non-paroxysmal AF patients [1, 6, [8] [9] [10] . Additional treatments, such as linear ablation or complex fractionated electrogram (CFE) ablation, have been implemented to modify the substrate and improve clinical outcome. CFE ablation, either alone or in addition to PVI, has been investigated, but the published results remain controversial [1, [3] [4] [5] 11] . We have evaluated the long-term results in non-paroxysmal AF patients following adjunctive CFE ablation to PVI. We also investigated potential predictors of long-term failure.
Methods

Population
Sixty-six consecutive non-paroxysmal AF patients [19 persistent, 47 long-standing persistent, aged 58±9 (range 35-80 years) and 86.4 % male], who had undergone radiofrequency ablation, were enrolled in this study. All patients were highly symptomatic and refractory to at least one anti-arrhythmic drug (AAD). Structural heart diseases presented in 11 (16.7 %) patients (seven with coronary heart disease, two with dilated cardiomyopathy, two with hypertrophic cardiomyopathy). Hypertension was present in 24 patients (36.4 %). Other clinical data such as duration of uninterrupted AF, AADs used, body mass index (BMI) and echocardiographic measurements, including left atrial diameter (LAD) and left ventricular ejection fraction (LVEF), were recorded (Table 1 ). The study protocol was approved by the Regional Ethics Committee of Western Norway.
Non-paroxysmal AF was defined as AF lasting more than 7 days and/or requiring cardioversion to be stopped. Persistent AF was defined as non-paroxysmal AF lasting less than one year, and long-standing persistent AF as lasting more than one year [12] .
Electrophysiological study and ablation procedure
All patients underwent the ablation procedure under conscious sedation. At the time of admission for the initial procedure, all the patients were in AF and had been using warfarin for at least 4 weeks. Heparin was administered after transseptal access and after the catheters had been placed in the left atrium (LA). Activated clotting time was kept between 250 and 350 s throughout the procedure. A 20-pole mapping catheter (Livewire™, Daig Co., St. Jude Medical, Minnetonka, MN, USA) was positioned in the right atrium (RA), with its distal poles in the coronary sinus (CS) and proximal poles around the tricuspid annulus. An open-irrigated ablation catheter was used for mapping and ablation (Navistar™, Biosense Webster or CoolPath™, St. Jude Medical). Cooling flow was set at a rate of 2-20 ml/min. Radiofrequency energy was delivered in temperature-controlled mode with a cut-off at 50°C and a power limit of 30-35 W for 60 s at each site. PVI was performed in all the patients by ablating at the PV ostia and confirmed by means of a 10-pole circular catheter (Lasso™, Biosense Webster or Optima™, St. Jude Medical). CFE mapping was performed with the aid of the mapping tools of the three-dimensional navigation systems (CARTO™, Biosense Webster or EnSite™, St. Jude Medical), by sampling electrograms from the distal electrode of the ablation catheter for 2.5 and 5 s, respectively. Additionally, all CFE areas were visually confirmed by the operators before ablation. Areas with cycle lengths of atrial electrograms <120 ms were targeted for ablation, with the endpoint of defragmentation of all the signals [3, 13] . CFE mapping and ablation were performed after PVI in the LA and CS in all the patients at the initial procedure. Additional CFE ablation in the RA was performed in selected patients at the operator's discretion.
Any atrial tachycardias (AT) that arose during CFE ablation were also targeted in the index procedure. In these cases, ablation was aimed at the critical isthmus after activation mapping or entrainment pacing. In this study, we did not perform linear ablation except for a few patients with macro-reentrant AT.
Patients who were still in AF after ablation were converted with direct current at the end of the procedure. Cavotricuspid isthmus ablation was performed after cardioversion in those patients who had clinical documentation of typical atrial flutter.
Follow-up
Patients were monitored for 24-48 h after the procedure, and low-molecular heparin was administered subcutaneously. Patients were discharged under oral warfarin. Anticoagulation and AADs were continued for at least 3 months. All patients were instructed to contact their referring doctor if symptoms suggestive of arrhythmia occurred. All patients were followed on an ambulatory basis with clinical evaluation, ECG and 24-h Holter recordings performed at 3, 6 and 12 months after the procedure. After the first ambulatory visit, AADs and anticoagulation were adjusted or stopped according to the clinical situation. After the first year, all the patients were contacted and the frequency of further follow-up depended on the clinical situation. If necessary, repeat procedures were scheduled at least 6 months after the first ablation procedure. Patients with recurrences of paroxysmal arrhythmias underwent an electrophysiological study. PVI was obtained again and AT ablation performed, if presented. Patients with recurrences of nonparoxysmal AF underwent repeated PVI+CFE ablation (Fig. 1) . Linear ablation was performed strictly only in those with incessant macro-reentrant AT.
Any documented episode of AF or AT after a blanking period of 3 months was regarded as recurrence. In accordance with the expert consensus statement on catheter ablation of AF, follow-up outcome was classified as: arrhythmiafree (stable SR throughout the follow-up without any atrial arrhythmia), clinical improvement (stable SR for long time but with short-lasting paroxysmal atrial arrhythmias) or failure (recurrence of persistent atrial arrhythmias) [12] . Both arrhythmia-free and clinical improvement were considered to be procedural benefits.
Statistical analysis
Continuous variables are presented as mean±standard deviation and compared using unpaired Student's t test. Categorical variables are presented as fractions (percentages) and compared 
Results
Ablation results
A total of 112 procedures were performed on 66 patients (mean 1.7±0.7 per patient). Mean procedural time was 279±83 min, fluoroscopy time 48±22 min and ablation time 79±30 min. All pulmonary veins were successfully isolated. Fifty-four patients (81.8 %) underwent adjunctive CFE ablation only in the LA and CS during the first procedure. Extensive CFE ablation targeting the LA, CS and RA was performed on 28 patients (42.4 %): in 12 during the initial procedure and in 16 during the repeat procedures. SR was restored by ablation in 41 procedures (36.6 %) at the end of the procedure, either directly from AF (in 18) or via AT (in 23). Twenty-five patients (37.9 %) developed an AT following PVI+CFE ablation. In 13 cases, the AT was ablated at the index procedure and did not recur. In the remaining 12 patients, a repeat procedure was necessary to target AT. Of those with AT, linear ablation (mitral isthmus or/and roof line) was performed in 11 and focal ablation in the other 14 patients. Cavotricuspid ablation was performed in 10 patients with manifest or clinically documented typical atrial flutter.
Repeat procedures
Thirty-six patients (54.5 %) underwent multiple procedures (up to four; Fig. 1 ). The average interval between the first and the second procedure was 20±10 months. During the repeat procedures, PVI was performed in all due to manifest electrical reconnection of one or more pulmonary veins, and AT was targeted in 12 patients (see also ablation results). Twelve out of 12 who started the repeat procedure in SR and eight out of eight who started in AT displayed a procedural benefit, compared to nine out of 16 of those who started the repeat procedure in persistent AF (p<0.05).
Complications
A total of five major complications were recorded (4.5 %) including two cardiac perforations that required pericardiocentesis (one) or surgical repair (one), two major groin hematomas that required further hospitalisation and one patient who required permanent pacemaker implantation after ablation in the RA. No atrio-esophageal fistula or cerebrovascular events were observed.
Follow-up
After the first ablation procedure, 21 (31.8 %) patients were arrhythmia-free (Fig 2a) , 20 (30.3 %) had clinical improvement and 25 (37.9 %) suffered recurrences of persistent atrial arrhythmias (Table 2) . With multiple procedures and after a mean follow-up of 40±14 months from the first and 28±15 months from the last procedure, 38 (57.6 %) were arrhythmia-free (Fig. 2b) , 15 (22.7 %) displayed clinical improvement and 13 (19.7 %) suffered recurrences of persistent atrial arrhythmias ( Table 2 ). As shown in the Kaplan-Meier curves most recurrences occurred within the first 12 months. Of those with clinical improvement, most had been arrhythmia-free for a long period and had only few episodes of self-terminating atrial arrhythmias. Among the 38 arrhythmia-free patients, 22 (57.9 %) had discontinued all AAD while the others (42.1 %) continued with betablockers because of other cardiovascular diseases. Only two patients among those with clinical improvement and none among those with recurrences of persistent arrhythmias had discontinued all AAD.
Predictors of long-term failure
Females displayed poorer long-term outcomes than males (arrhythmia-free 22.2 vs. 63.2 %, p<0.05). More females (p<0.01) and longer uninterrupted AF duration (p<0.001) were found among the patients with failure than among those who displayed procedural benefit (Table 1 ). Univariate analysis revealed that female gender and duration of uninterrupted AF were independent predictors of long-term procedural failure (p=0.008 and 0.004 respectively, OR 7.65 and 1.35 respectively). These results were only partially modified after adjusting for age, BMI, LAD, LVEF, the presence of structural heart disease and hypertension in multivariate analysis (Table 3) . Grouping the patients in terms of uninterrupted AF duration ≤1 year (persistent AF patients), 1-2, 2-4 and >4 years showed that the rates of procedural benefit were 100.0, 86.7, 83.3 and 57.1 %, respectively. Similarly, the proportions of arrhythmiafree patients were 72.2, 66.7, 66.7 and 33.3 %, respectively (Fig. 3) . A statistically significant difference was found between those in whom AF duration was >4 years and those with a duration of ≤1 year (p=0.01), 1-2 years (p=0.04), and nearly significant with those with a duration of 2-4 years (p = 0.06). Cumulative results displayed a significantly higher rate of arrhythmia-free patients when the duration of AF had been ≤2 and ≤4 years than when it was >4 years (p<0.01, Table 2 ). ROC analysis showed an area under the curve of 0.80 (95 % C.I. 0.69-0.92; p<0.001) and identified 3.5 years as the optimal cut-off point for predicting recurrence of persistent AF/AT (sensitivity 85 %, specificity 74 %).
Discussion
Main findings
After a mean follow-up time of 40±14 months following multiple PVI+CFE ablation procedures, 53 patients (80.3 %) experienced clinical benefit from the ablation procedure(s), with freedom from arrhythmias in 38 and clinical improvement in 15. Multiple procedures were required in 54.5 % of the patients. Atypical AT was observed and treated in 37.8 % of patients after CFE ablation. Female gender and long duration of uninterrupted AF were found to be independent predictors of long-term failure.
Challenges of CFE ablation
Nademanee et al. reported excellent long-term results (SR maintenance >90 %) both in paroxysmal and nonparoxysmal AF patients by using stand-alone CFE ablation without PVI [3] . Few studies could reproduce these outcomes. Oral et al. described poor long-term results (33 %) with the same technique in non-paroxysmal AF patients [4] and found no adjunctive benefits of extensive CFE ablation (up to 2-h extra procedure time) following PVI (SR maintenance 36 vs. 34 %) [5] . On the other hand, two recent metaanalyses have demonstrated that adjunctive PVI+CFE ablation produces a higher rate of arrhythmia-free survival than stand-alone PVI (SR maintenance 62 vs. 47 % and 65 vs. 42 %, respectively) in non-paroxysmal AF patients [8, 9] .
The clinical outcomes of CFE ablation are still controversial. It is likely that the reasons for these discrepancies lie in a lack of consensus on the concept of CFE, including definition (criteria), mapping (automated detection vs. visual inspection), ablation strategy and endpoint (defragmentation vs. electrogram silencing). Automated CFE mapping tools allow reliable and reproducible CFE mapping [14] [15] [16] . Although Hunter et al. showed that visual inspection of the CFE is reliable and correlates well with automated detection [17] , the endpoint for CFE ablation in this case is less welldefined. Furthermore, in many centres CFE ablation by visual inspection is performed with a look-and-ablate approach. This strategy does not provide a comprehensive understanding of the level of fractionation before ablation. Ultimately, it is also possible that CFE adjacent to an ablation site may be affected during ablation. Once CFE areas have been defined, ablation can be performed with the aim of either regularizing (defragmenting) or abolishing (silencing) the electrograms. Although no study has evaluated this issue, these two different strategies are likely to impact both AF recurrences and the onset of post-ablation ATs.
In spite of the longer procedural and ablation times, the incidence of procedure-related complications in our series (4.5 %) was comparable to those reported from single-centre and multi-centre surveys [6, [18] [19] [20] . This suggests that extensive CFE ablation does not increase the risk of complications.
The post-ablation AT issue
Post-ablation AT has been frequently reported as a consequence of LA substrate modification [2, 21] . The incidence of AT in our series was relatively high (37.8 %), but was consistent with other published data [2, 21, 22] . The ATs observed during the procedures were probably the consequence of progressive AF "organization" and could be related to the creation of slow conduction areas during atrial defragmentation. As suggested above, silencing of CFE instead of defragmentation may help to reduce the incidence of post-ablation ATs. As suggested by Ammar et al. and confirmed by our results, the occurrence and successful treatment of an AT arising from non-paroxysmal AF patients led to better clinical results at long-term follow-up [21] .
Negative predictors and clinical implications
Several parameters such as age, sex, AF duration, AF cycle length, BMI, LVEF, LAD, presence of hypertension or structural heart disease have been evaluated as potential predictors of long-term failure [11, [23] [24] [25] [26] [27] [28] [29] . In our population, only female gender and longer duration of uninterrupted AF were associated with failure of ablation procedures.
Female patients seem to have fewer symptoms and appear to be referred later to ablation [11, 28] . Furthermore, a higher incidence of non-PV foci has been observed in females than in males [28] . Duration of uninterrupted AF has been related to a progressive remodelling of the LA that leads to increased fibrogenesis and dilation of the atria. Matsuo et al. found higher rates of arrhythmia recurrence in patients whose AF lasted longer than 21 months using a stepwise ablation strategy, and therefore suggested that a duration of uninterrupted AF <2 years might represent a prudent indication for ablation of non-paroxysmal AF [26] . Our results show that 69.7 and 68.9 % of patients in whom AF lasted for ≤2 and ≤4 years were arrhythmia-free after multiple procedures of PVI+CFE ablation, compared to 33.3 % of those with a duration of >4 years. This indicates that the patients with longer uninterrupted AF history (up to 4 years) may benefit of this ablation strategy. Moreover, recent studies have shown that the conversion and maintenance of SR prior to the ablation procedure leads to better short-and long-term outcomes [30, 31] . These results suggest that the remodelling process can be interrupted and even reversed by conversion to SR. The development of a strategy that could integrate SR restoration and maintenance before ablation seems to be reasonable and deserves future study.
Limitations
This was a retrospective, observational study with a relatively small number of patients. As in other similar studies, ECG and 24-h Holter recordings were used as monitoring tools during long-term follow-up [12] , so partly asymptomatic recurrences of paroxysmal arrhythmias may not have been detected. We employed different systems for CFE mapping with different sampling periods (limited by the system). Although we visually inspected all electrograms to assure that all CFE areas were ablated, this may have had an impact on the achievement of ablation. Finally, we could not avoid performing a linear ablation in a few patients because of incessant AT. We realise that this may limit the data interpretation. On the other hand, ablation of iatrogenic AT may be an intermediate step in the treatment of some non-paroxysmal AF patients.
Conclusions
After long-term follow-up, a strategy of combined PVI+CFE ablation seems to provide a reasonable rate of arrhythmia-free and clinical improvement in non-paroxysmal AF patients. Patients with uninterrupted AF duration ≤4 years appear to benefit most from this ablation strategy. Female gender and longer duration of uninterrupted AF are predictors of longterm failure.
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